Targeted LNPs for Extrahepatic Delivery Market Report 2026

The targeted lnps for extrahepatic delivery market size has grown exponentially in recent years. It will grow from $1.81 billion in 2025 to $2.19 billion in 2026 at a compound annual growth rate (CAGR) of 20.7%. The growth in the historic period can be attributed to success of hepatic LNP delivery systems, growth in mRNA vaccine platforms, expansion of nanomedicine research, rising gene therapy trials, increased biologic drug delivery challenges.

The targeted lnps for extrahepatic delivery market size is expected to see exponential growth in the next few years. It will grow to $4.68 billion in 2030 at a compound annual growth rate (CAGR) of 20.9%. The growth in the forecast period can be attributed to growing pipeline of RNA therapeutics, rising demand for tissue targeted delivery, expansion of precision drug delivery platforms, increasing oncology nanoparticle research, higher biotech delivery partnerships. Major trends in the forecast period include extrahepatic targeted LNP formulations, ligand directed nanoparticle delivery, tissue specific RNA delivery systems, advanced ionizable lipid designs, modular targeted nanocarrier platforms.

The growing demand for personalized medicine (PM) is expected to propel the growth of the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market in the coming years. Personalized medicine refers to therapeutic approaches designed around an individual’s genetic makeup, disease profile, or biomarkers to enhance treatment effectiveness while reducing adverse effects. Advancements in molecular diagnostics, biomarker discovery, and precision-focused drug development are accelerating the adoption of personalized therapies. Targeted lipid nanoparticles play a vital role in advancing personalized medicine by enabling accurate delivery of therapeutic agents to specific tissues or cell types, including extrahepatic targets, thereby improving treatment efficacy and safety. For instance, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. Therefore, the increasing demand for personalized medicine is contributing to the growth of the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market.

Leading companies operating in the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market are focusing on technological advancements in targeted LNP platforms, including DARPin-conjugated systems, to enhance selective delivery to immune and tissue-specific cells. DARPin-conjugated lipid nanoparticles refer to LNPs functionalized with Designed Ankyrin Repeat Proteins (DARPins), which are engineered binding proteins capable of highly specific interactions with selected cell surface receptors. This targeting capability allows for improved uptake by specific cell types, supporting extrahepatic applications such as immune cell modulation and tissue-specific gene delivery. For example, in November 2025, Acuitas Therapeutics Inc., a Canada-based biotechnology company, introduced next-generation LNP technologies designed for extrahepatic targeting, including platforms aimed at T-lymphocyte delivery, mucous-penetrant formulations for airway epithelial cells, and a pre-formed vesicle manufacturing approach intended to improve scalability, cost efficiency, and storage stability. These advancements expand the potential applications of mRNA-LNP therapeutics beyond the liver and support broader use cases in gene editing, vaccines, and personalized medicine.

In August 2025, AbbVie Inc., a US-based biopharmaceutical company, acquired Capstan Therapeutics Inc. for an undisclosed amount. With this acquisition, AbbVie aims to advance in vivo targeted lipid nanoparticle (tLNP) therapies and accelerate the development of ribonucleic acid (RNA)-based treatments for B cell-mediated autoimmune diseases. Capstan Therapeutics Inc. is a US-based clinical-stage biotechnology company developing in vivo CAR-T therapies through its proprietary targeted lipid nanoparticle (tLNP) platform, CellSeeker.

Major companies operating in the targeted lnps for extrahepatic delivery market are Pfizer Inc., Sanofi S.A., Merck KGaA, FUJIFILM Pharmaceuticals U.S.A. Inc., Evonik Industries AG, Recipharm, CordenPharma International GmbH, Ardena Nanomedicines, Arcturus Therapeutics Holdings Inc., BIOVECTRA Inc., Ascendia Pharmaceuticals Inc., ABITEC Corporation, Creative Biolabs, Genevant Sciences GmbH, Polymun Scientific Immunbiologische Forschung GmbH, ST Pharm, eTheRNA immunotherapies NV, NanoVation Therapeutics, DIANT Pharma, Curapath, Phosphorex Inc.

Tariffs on specialty lipids, nanoparticle formulation materials, and precision lab equipment are increasing production costs in the targeted lipid nanoparticles market. Import duties on high purity lipids and targeting ligands are affecting advanced formulation segments most strongly. Companies dependent on cross border raw material sourcing are facing margin pressure. Research and pilot manufacturing programs are seeing higher input expenses. Vendors are developing regional supplier networks and local synthesis capacity. Some tariffs are encouraging domestic lipid manufacturing investment. This is improving long term supply stability and formulation control.

The targeted lnps for extrahepatic delivery market research report is one of a series of new reports that provides targeted lnps for extrahepatic delivery market statistics, including targeted lnps for extrahepatic delivery industry global market size, regional shares, competitors with a targeted lnps for extrahepatic delivery market share, detailed targeted lnps for extrahepatic delivery market segments, market trends and opportunities, and any further data you may need to thrive in the targeted lnps for extrahepatic delivery industry. This targeted lnps for extrahepatic delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Targeted lipid nanoparticles for extrahepatic delivery are advanced nanotechnology-based systems created to transport therapeutic agents to organs and tissues outside the liver with high precision. These platforms use optimized lipid formulations and targeting approaches to improve cellular absorption, enhance distribution, and reduce unintended accumulation. They play an essential role in increasing the effectiveness and safety of modern treatments by enabling controlled delivery beyond liver tissues.

The primary product types of targeted lipid nanoparticles for extrahepatic delivery include ionizable lipid-based lipid nanoparticles, cationic lipid-based lipid nanoparticles, polyethylene glycol-coated lipid nanoparticles, and other lipid nanoparticle formulations. Ionizable lipid-based lipid nanoparticles are lipid carriers capable of altering their charge based on pH conditions, thereby enhancing cellular uptake and improving the delivery efficiency of nucleic acids or therapeutic agents. These nanoparticles are utilized across therapeutic areas such as oncology, infectious diseases, genetic disorders, metabolic disorders, and other therapeutic fields. They are applied in gene therapy, messenger ribonucleic acid (mRNA) vaccines, small interfering ribonucleic acid (siRNA) delivery, protein delivery, and other applications, and are used by end users including pharmaceutical companies, biotechnology firms, academic and research institutes, and other end users.

The targeted lipid nanoparticles for the extrahepatic delivery market consist of revenues earned by entities by providing services such as enhanced cellular uptake, targeted delivery, and protection of cargo. The market value includes the value of related goods sold by the service provider or included within the service offering. The targeted lipid nanoparticles for the extrahepatic delivery market also include sales of lipid nanoparticle formulations, targeting ligands, and delivery system components. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.